BPC-157: the gut-derived peptide with a broad preclinical healing profile

BPC-157 is a synthetic 15-amino-acid peptide (pentadecapeptide) with the sequence GEPPPGKPADDAGLV. It was originally identified in the gastric juice fraction studied by a research group at the University of Zagreb in the early 1990s, and three decades of primarily preclinical work have explored its effects across tendon, gut, wound, nerve, and cardiovascular models. It has no FDA approval, is prohibited by WADA, and as of 2026 its compounding status in the US remains in formal review.

What is BPC-157?

BPC-157 stands for Body Protection Compound 157, a name reflecting its origin in a larger "body protection" protein fraction isolated from human gastric juice. The "157" refers to its position within that parent sequence. It is a fully synthetic peptide, not extracted from tissue, and is produced by solid-phase peptide synthesis.

The foundational paper appeared in the Journal of Physiology, Paris in 1993, authored by Predrag Sikiric, Sven Seiwerth, and colleagues at the University of Zagreb School of Medicine in Croatia [1]. The conceptual frame from those early papers positioned the stomach as a central neuroendocrine organ whose protection is foundational to whole-organism stress coping, with gastric-juice-derived peptides as hypothesized mediators of a broad "organoprotection" response. BPC-157 was the specific sequence that showed reproducible cytoprotective effects in rat models and was selected for further development.

A key physicochemical property repeatedly cited in the literature is stability in human gastric juice for more than 24 hours, which is unusual for a small peptide and is the basis of the oral-route rationale [2]. Independent confirmation of this stability claim outside the originating laboratory is limited, which is a recurrent interpretive concern. The compound was later developed under the clinical designation PL 14736 by Pliva (subsequently Teva) for a phase 1 safety study and a phase 2 program in ulcerative colitis.

How does it work?

Unlike most therapeutically studied peptides, BPC-157 does not have a single identified receptor. The current model describes convergent effects on the nitric oxide system, VEGFR2 angiogenic signaling, FAK-paxillin focal adhesion signaling in fibroblasts, growth hormone receptor expression, and brain-gut axis neurotransmitter patterns. A newer hypothesis proposes that its triple-proline segment engages Src family kinase SH3 domains and could serve as an upstream node that feeds into the other observed pathways.

The longest-running mechanistic narrative centers on the nitric oxide (NO) system. Across models of both NO deficiency (such as L-NAME-induced hypertension) and NO excess, BPC-157 has been described as restoring NO homeostasis rather than acting as a uniform agonist or antagonist of any single nitric oxide synthase isoform [3]. This bidirectional modulation is biologically unusual and reflects the Zagreb group's broader framing of the peptide as a homeostasis-restoring agent rather than a simple stimulant or inhibitor.

At the vascular level, Hsieh and colleagues showed that BPC-157 upregulates VEGFR2 expression in hind-limb ischemia models and engages a VEGFR2-Akt-eNOS signaling axis [4]. This positions BPC-157 as a receptor-level potentiator of the angiogenic response rather than a direct growth-factor mimetic, a mechanistic distinction worth holding onto. In tendon fibroblasts specifically, Chang and colleagues demonstrated dose-dependent increases in phosphorylation of focal adhesion kinase (FAK) and paxillin, with parallel increases in fibroblast migration from tendon explants [5]. This FAK-paxillin mechanistic anchor is the cleanest single linkage in the BPC-157 literature for any one indication.

What does the evidence show?

The evidence base for BPC-157 is overwhelmingly preclinical and dominated by rat models from a single research lineage. The strongest claims are in tendon and ligament healing, gut cytoprotection, and wound healing, all with mechanistic anchors and multi-model consistency. The human evidence is extremely limited: a phase 1 safety study of rectal PL 14736 in healthy male volunteers reported tolerability, and a phase 2 program in ulcerative colitis did not produce a peer-reviewed efficacy publication.

In tendon models, Staresinic and colleagues demonstrated that BPC-157 given systemically or locally accelerates healing of transected rat Achilles tendon, while Krivic showed improved tendon-to-bone healing and opposition of corticosteroid-induced impairment [6]. The gut evidence is the oldest and broadest domain, with documented protection in gastric ulcer models induced by cysteamine, alcohol, stress, and NSAIDs, as well as improved healing of intestinal anastomoses and multiple fistula types across 30 years of Sikiric-lineage rat work. Wound healing studies include burn wound models and a diabetic excisional wound comparison against PDGF-BB, where BPC-157 stimulated earlier collagen organization.

The most important human data point is the phase 1 study of PL 14736 (rectal administration) in healthy male volunteers, which reported safe and well-tolerated outcomes at the abstract level. The phase 2 efficacy program in mild-to-moderate ulcerative colitis was conducted under PL 14736, but its results were never published in a peer-reviewed journal, which is a recurring concern in independent reviews of the field [7].

A single published preclinical pharmacokinetics package by He and colleagues (2022) in rats and beagle dogs reported an elimination half-life under 30 minutes after single intravenous or intramuscular doses, linear pharmacokinetics, and rapid metabolism to amino acids with no accumulation [8]. No peer-reviewed human pharmacokinetics study for any administration route has been published as of 2026.

The single-lab caveat

The most important interpretive caveat for the entire BPC-157 field is that the great majority of original efficacy and mechanism papers list Sikiric or Seiwerth as first or senior author. Independent replication of central claims outside this research lineage is limited, and this is the single biggest reason to apply heightened scrutiny before accepting any individual finding as established.

This does not mean the claims are wrong. Internal consistency across many injury models and mechanistic layers is the strongest argument for a real biological effect. A wide-range pharmacodynamic signal active across many models is meaningful if it holds up, but it should accelerate rather than substitute for independent replication. The most important next step for the field is a well-designed, adequately powered efficacy trial in a single indication from a sponsor with no conflict of interest in the outcome, preceded by a peer-reviewed human pharmacokinetics study.

Regulatory status in 2026

BPC-157 is not FDA-approved as a drug for any indication. It was placed on FDA's interim Category 2 bulk substances list for 503A compounding in 2023, and on April 15, 2026 FDA removed it, along with eleven other peptides, from Category 2, effective April 22. That removal cleared a safety objection; it did not grant compounding access. On July 23-24, 2026 the Pharmacy Compounding Advisory Committee (PCAC) voted, non-bindingly, to recommend BPC-157 (with KPV, TB-500, MOTS-c, epitalon, and semax) for the 503A bulks list, over the FDA's own reviewers, who had recommended against all seven peptides on the agenda. A recommendation is not a decision: the FDA has not adopted it, adding a substance to the list would still require formal rulemaking, and BPC-157 remains not FDA-approved and not legal to compound.

For athletes under WADA jurisdiction, the status is clear and does not depend on the compounding debate: BPC-157 is prohibited under category S0 (non-approved substances) at all times, in-competition and out-of-competition, and athlete sanctions involving BPC-157 have been issued [9]. The Department of Defense Operation Supplement Safety program also flags BPC-157 as a prohibited peptide and an unapproved drug found in health and wellness products. Regulatory status statements in any educational context should always carry a date, as this area continues to evolve.

Where it fits in the healing-peptide landscape

BPC-157's closest comparators in the healing-peptide space are thymosin beta-4 / TB-500, GHK-Cu, and KPV. Each operates through a different primary mechanism, occupies overlapping community narratives, and shares the common limitation of no controlled human efficacy trial for its marketed indications.

TB-500 (a fragment of thymosin beta-4) is marketed in the same musculoskeletal-recovery niche and shares the angiogenesis-and-migration mechanistic narrative, but the broader thymosin beta-4 literature is more independent than the BPC-157 base and includes cardiac and ocular programs. GHK-Cu is a copper tripeptide focused on dermal and cosmetic biology, with its primary mechanism being transition-metal delivery and gene-expression effects rather than the NO-system and vascular focus of BPC-157. KPV is the gut-inflammation comparator, with PepT1-mediated uptake and NF-kappaB suppression as its mechanistic story, which differs entirely from BPC-157's vascular and cytoprotective model. For context on how peptides interact with systemic endocrine signals like the GH axis and the incretin family that includes semaglutide, the underlying biology is covered in our free peptides and your body module.